Latest Regulatory Progress News

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Aeris Resources has announced a maiden open pit Probable Ore Reserve for its Constellation Project in New South Wales, underpinning a 5-to-7-year mine life and leveraging existing Tritton processing infrastructure.

Element 25 Limited has raised AU$10 million to advance its Butcherbird Expansion Project in Western Australia, aiming to increase manganese production and support its innovative battery materials refinery in the US.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Australian Critical Minerals has completed a strategic acquisition of Circuit Resources, adding six multi-commodity projects in Peru and initiating exploration activities with drilling planned for late 2025.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Audalia Resources completed key drilling and metallurgical programs at its Medcalf vanadium-titanium-iron project, progressing towards a resource upgrade and mine design. However, cash reserves and funding runway remain limited, underscoring the need for successful financing.

Lake Resources has strengthened its financial position with a $12 million capital raise and delivered a 16% cut in capital expenditure for its flagship Kachi Lithium Brine Project, advancing its path toward low-cost lithium production.

Whitehaven Coal reported a steady start to FY26 despite a 15% drop in quarterly production, with cost-saving initiatives on track and a strong balance sheet supporting ongoing projects.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

E79 Gold Mines has reported outstanding high-grade copper and gold assay results from its Mountain Home Project in the Northern Territory, significantly expanding the known mineralised area and setting the stage for drilling in 2026.